Durec­t's non-opi­oid painkiller brush­es aside check­ered past, gain­ing FDA ap­proval in shoul­der surg­eries

5 years ago
FDA+

Two years af­ter flop, Verona gets a win as it preps for piv­otal Phase III tri­als

5 years ago
R&D

Pfiz­er pre­dicts a $15B avalanche of cash from its Covid-19 vac­cine in 2021 as the R&D team claims a big spike in the ...

5 years ago
Coronavirus

Eli Lil­ly's new can­cer R&D chief has some things to say about drug dis­cov­ery, the dif­fi­cul­ty in find­ing new drugs to ...

5 years ago
People
R&D

Im­muno­vant vol­un­tar­i­ly halts stud­ies on sole drug af­ter sur­prise cho­les­terol find­ings, FcRn ri­val ar­genx surges

5 years ago
R&D

Ver­tex is poised for a shop­ping spree. But it’s still un­clear just what might go in­to their bas­ket — and at least ...

5 years ago
Deals

Covid-19 roundup: In­ter­im analy­sis sug­gests Russ­ian vac­cine is 91.6% ef­fec­tive; US inks big deal with Aus­tralian ...

5 years ago
Coronavirus

2020 re­port cards con­tin­ue rolling in, with an­a­lysts de­tail­ing record-break­ing fundrais­ing for the UK

5 years ago
Financing

Bris­tol My­ers flags an­oth­er PhI­II suc­cess for one of their top block­buster prospects, clear­ing a path to the FDA

5 years ago
R&D

In­spec­tions: GAO calls on FDA to plan for back­log, re­view al­ter­na­tives

5 years ago
FDA+

Af­ter ran­corous threats and a clin­i­cal hold, Ap­plied Ther­a­peu­tics is set to re­sume pe­di­atric galac­tosemia study

5 years ago
FDA+

Con­cert crushed on PhII schiz­o­phre­nia flop; Am­gen's so­tora­sib gets BTD in Chi­na

5 years ago
News Briefing

Ar­cutis show­cas­es pos­i­tive PhI­II da­ta show­ing its top­i­cal cream scratched the sweet spot Ote­zla or steroids could­n't

5 years ago
R&D

Who are the young bio­phar­ma lead­ers shap­ing the in­dus­try? Nom­i­nate them for End­points' spe­cial re­port

5 years ago
Editor's note

The packed PD-(L)1 game just got an­oth­er play­er — a low-pro­file biosim­i­lars com­pa­ny look­ing to branch out with a ...

5 years ago
Deals

Ex­clu­sive: Johns Hop­kins pro­fes­sor and biotech col­leagues tout new tech to test Covid-19 vac­cine re­sponse

5 years ago
Coronavirus
Manufacturing

Khosla Ven­tures helps seed a next-gen re­gen­er­a­tive med­i­cines start­up boast­ing AI-based stem cell cul­tur­ing tech­nol­o­gy

5 years ago
Financing
Cell/Gene Tx

Ex­clu­sive: Third Rock­'s stealthy MO­MA Ther­a­peu­tics taps a long­time Mil­len­ni­um, Take­da vet as CEO

5 years ago
People

Hori­zon nabs an­oth­er rare dis­ease pipeline for the port­fo­lio in $3B buy­out. And As­traZeneca — a fu­ture ri­val — is ...

5 years ago
Deals

Biotech part­ner drops Glax­o­SmithK­line’s ad­ju­vant as it moves Covid-19 vac­cine in­to PhII/III, cit­ing ...

5 years ago
Deals
Coronavirus

Covid-19 roundup: Bay­er ex­pands deal with Cure­Vac to pro­duce shots; UK or­ders more Val­ne­va vac­cines

5 years ago
Coronavirus

In pur­suit of an HIV cure, Gilead jumps in­to a T cell-dri­ving vac­cine pro­gram with a $785M deal that trig­gers PhI

5 years ago
Deals

#WCLC21: Mer­ck pokes Bris­tol My­ers in the eye with Keytru­da da­ta show­ing safe­ty red flags in Yer­voy com­bo tri­al

5 years ago
Pharma

#WCLC21: As­traZeneca's EGFR in­hibitor Tagris­so cuts re­lapse, death risks in pa­tients with and with­out pri­or ...

5 years ago
Pharma
First page Previous page 740741742743744745746 Next page Last page
A service from the Financial Times